Early trial aims to zap advanced prostate cancer with targeted radiation and chemo
Disease control
Not yet recruiting
This early-stage study is testing the safety of combining a standard chemotherapy drug (docetaxel) with a newer targeted radiation drug (Lutetium-PSMA) for men with advanced prostate cancer that has spread and is no longer controlled by hormone therapy. The main goal is to find t…
Phase: PHASE1 • Sponsor: Instituto do Cancer do Estado de São Paulo • Aim: Disease control
Last updated Mar 30, 2026 14:30 UTC